BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization

December 8, 2008

PRINCETON, N.J., Dec. 8 /PRNewswire/ — BioWa, Inc., announced today that
it licensed to GlaxoSmithKline (NYSE: GSK) its POTELLIGENT(R) Technology for
use in developing and commercializing select GSK antibodies with enhancement
of antibody-dependent cellular cytotoxicity (ADCC).

“GSK is recognized as a key player in the field of antibody drug
discovery,” said Dr. Masamichi Koike, BioWa President and CEO. “We believe
this represents an important opportunity to promote the development of more
effective targeted treatments for debilitating diseases where enhanced ADCC
might offer a significant therapeutic benefit.”

Under the terms of the agreement, BioWa will provide GSK with non-
exclusive commercial rights to use the technology for multiple antibodies. In
return, BioWa will receive technology access fees, and may receive milestone
payments and royalties from resulting products which are developed by GSK.
Additional terms were not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody
therapeutics, by enhancing ADCC, one of the major mechanisms of action for
antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the
amount of fucose in the carbohydrate structure of an antibody using a
proprietary fucosyltransferase-knockout CHO cell line as a production cell.
Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC
activity of an antibody in vitro, and significantly increases potency and
efficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies are
being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan’s
leading pharmaceutical and largest biotech company, and is the exclusive
worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform
consists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating a
superior antibody molecule with enhanced ADCC and CDC activities. BioWa is
offering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under a
license to maximize the value of these technologies. Together with Kyowa Hakko
Kirin, BioWa is focused on development of ADCC/CDC enhanced monoclonal
antibody-based therapeutics to fight cancer and other life-threatening and
debilitating diseases. For more information about BioWa, visit its web site at

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of
Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

SOURCE BioWa, Inc.

Source: newswire

comments powered by Disqus